Thync raises $13M led by Khosla Ventures for mood altering device, expected to ship 2015
Thync Raises $13 Million for Its Brain-Stimulating Electrodes — In a windowless conference room at Thync, a secretive startup in Los Gatos, Calif., I recently tried what may be Silicon Valley's strangest new product in years.
Context & Ripple Effects
There is no earlier arc in the file: this is the first public beat for Thync itself, a secretive Los Gatos startup that Businessweek got a demo from and that now has a confirmed $13 million round led by Khosla Ventures, with shipping targeted for 2015. What makes the story travel is the breadth of same-day pickup — SiliconBeat, TechCrunch, the Wall Street Journal, Business Insider and others all carried it on or about October 9, 2014 — unusual visibility for a product nobody outside the demo room has used.
The investor side is what anchors it in a pattern: Khosla Ventures closed a $1.05 billion fund in 2011 that it said would go to clean tech and mobile, so an unproven consumer neurostimulation bet marks a stretch beyond the fund's stated thesis, made while the category has no shipped product.
First-order effects
- The $13 million gives Thync the runway to take its mood-altering electrode wearable from secret demos to a planned 2015 consumer launch, with Khosla Ventures as the validating anchor.
- The same-day pickup by eight-plus outlets hands an unshipped product mainstream attention most hardware startups only earn at launch.
Second-order effects
- Khosla's lead role pulls a firm whose last mega-fund was earmarked for clean tech and mobile into consumer brain hardware, raising the odds its later deals follow the same direction.
- A high-visibility claim like 'altering your mood with electrodes' invites scrutiny of how such a product will be categorized — wellness gadget versus medical device — before Thync ever reaches shelves.
Third-order effects
- If the 2015 ship happens and sells, venture money starts treating neurostimulation as a consumer category rather than a clinical one, forcing regulators and buyers to decide which claims about changing mental state belong in a retail box.
- The broader structure it points toward: brain-interface companies funded at the platform stage, years before efficacy standards for the category exist.
The trend: Venture capital is pulling brain stimulation out of clinics and into consumer wearables, with top-tier firms placing bets before the category has a single shipped product.